Tonix Pharmaceuticals Holding Corporation (TNXP) News

Form 8-K - Current report

Tonix Pharmaceuticals Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for TNX-102 SL for the Management of Fibromyalgia

On track for August 15, 2025 FDA PDUFA goal date TNX-102 SL is a non-opioid analgesic; if approved, TNX-102 SL...

Form PRE 14A - Other preliminary proxy statements

Form ARS - Annual Report to Security Holders

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved...

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025

CHATHAM, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix...

Form 8-K - Current report

Tonix Pharmaceuticals Announces Grant by Medical CBRN Defense Consortium (MCDC) for Development of TNX-801, the Company’s Single-Dose Mpox and Smallpox Vaccine Candidate

The World Health Organization (WHO) recently reaffirmed the spread of new clade Ib Mpox a public health...

Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit

CHATHAM, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix...

Form 8-K - Current report

Form 8-K - Current report

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia

TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable...